Skip to main content
SYKStryker CorporationSell5.2·$307.80-1.41%
Open full analysis

Stryker Corporation (SYK) Stock Analysis

Recovery setup

SellModerate Confidence

Healthcare · Medical Devices

Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $307.80 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: sole-source suppliers; Weak growth.

Stryker is a global medical technology company with $25.1 billion in 2025 net sales across two segments: MedSurg and Neurotechnology (62%) and Orthopaedics (38%), selling surgical equipment, navigation systems, joint implants, and Mako robotic-arm technology to hospitals and... Read more

$307.80+13.0% A.UpsideScore 5.2/10#28 of 40 Medical Devices
QualityF-score9 / 9FCF yield3.64%
IncomeYield1.13%(5y avg 0.99%)Payout39.81%sustainable
Stop $291.08Target $348.12(analyst − 10%)A.R:R 2.4:1
Analyst target$386.80+25.7%25 analysts
$348.12our TP
$307.80price
$386.80mean
$465

Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $307.80 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: sole-source suppliers; Weak growth. Chart setup: Death cross but MACD improving, RSI 46. Score 5.2/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 45d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-15
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Jul 30, 202645d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (3/4)
High-quality business
Risks
Concentration risk — Supplier: sole-source suppliers
Weak growth
Negative momentum

Key Metrics

P/E (TTM)36.1
P/E (Fwd)18.7
Mkt Cap$119.7B
EV/EBITDA19.1
Profit Mgn13.2%
ROE15.2%
Rev Growth2.6%
Beta0.79
Dividend1.13%
Rating analysts35

Quality Signals

Piotroski F9/9MoatNarrow

Options Flow

P/C12.26bearish
IV53%elevated
Max Pain$450+46.2% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHSuppliersole-source suppliers
    10-K Item 1A: 'several raw materials, components, finished devices and services are procured from a sole source due to, among other things, the quality considerations, unique intellectual property considerations or constraints associated with regulatory requirements'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
2.0
Value Rank
2.9
Quality Rank
7.7

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Ma Position
4.0
Rsi
4.5
Macd
10.0
Volume distribution (falling OBV)Below 200-MA, MA slope -3.4%/30d — confirmed downtrend
GatesMomentum 3.9<4.5Death cross (50MA < 200MA)A.R:R 2.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 45d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
46 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $290.96Resistance $322.87

Price Targets

$291
$348
A.Upside+13.1%
A.R:R2.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! momentum at 3.9 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-07-30 (45d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SYK stock a buy right now?

Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $307.80 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: sole-source suppliers; Weak growth. Chart setup: Death cross but MACD improving, RSI 46. Prior stop was $291.08. Score 5.2/10, moderate confidence.

What is the SYK stock price target?

Take-profit target: $348.12 (+13.0% upside). Prior stop was $291.08. Stop-loss: $291.08.

What are the risks of investing in SYK?

Concentration risk — Supplier: sole-source suppliers; Weak growth; Negative momentum.

Is SYK overvalued or undervalued?

Stryker Corporation trades at a P/E of 36.1 (forward 18.7). TrendMatrix value score: 5.1/10. Verdict: Sell.

What do analysts say about SYK?

35 analysts cover SYK with a consensus score of 4.1/5. Average price target: $387.

What does Stryker Corporation do?Stryker is a global medical technology company with $25.1 billion in 2025 net sales across two segments: MedSurg and...

Stryker is a global medical technology company with $25.1 billion in 2025 net sales across two segments: MedSurg and Neurotechnology (62%) and Orthopaedics (38%), selling surgical equipment, navigation systems, joint implants, and Mako robotic-arm technology to hospitals and surgeons in approximately 61 countries. No commercial customer accounted for more than 10% of net sales in 2025.

Related stocks: DXCM (DexCom, Inc.) · BSX (Boston Scientific Corporation) · SNN (Smith & Nephew SNATS, Inc.) · ZBH (Zimmer Biomet Holdings, Inc.) · MDT (Medtronic plc.)
Home Stocks SYK

Latest news

Latest News

MarketBeat47d ago
MarketBeat48d ago
Cổng thông tin điện tử tỉnh Lào Cai54d ago
MarketBeat55d ago
MarketBeat55d ago
GuruFocus55d ago
Yahoo Finance55d ago
Yahoo Finance46d agoEarnings
StockStory46d ago
TradingView46d ago
Quiver Quantitative46d ago
Moomoo46d agoEarnings
The Globe and Mail47d ago
MSN47d agoEarnings
MSN53d agoEarnings
MSN54d ago
Yahoo Finance54d ago
Cổng thông tin điện tử Tỉnh Sơn La54d ago
MarketBeat51d ago
MarketBeat51d ago
Loading more...